Related by context. All words. (Click for frequent words.) 74 Antiviral Activity 71 Safety Tolerability 71 Pharmacodynamics 69 Tolerability 68 Pharmacokinetic 68 Placebo Controlled Trial 67 Controlled Study 67 See CLINICAL PHARMACOLOGY 67 Anti Tumor Activity 67 Immunogenicity 67 Study Evaluating 67 Orally Active 66 Small Molecule 66 Pharmacokinetic Study 66 Randomized Double Blind Placebo 66 Double Blind Placebo 66 Dose Response 66 Antitumor Activity 66 Controlled Trial 66 Kinase Inhibitor 66 Oral Fingolimod 66 Anti Tumor 65 Pharmacokinetics PK 65 Long Term Efficacy 65 Prolongs Survival 65 Well Tolerated 65 Bortezomib 65 Recombinant Human 65 Efficacy 65 Demonstrates Potent 65 Parathyroid Hormone 65 Double Blind Randomized 65 Capecitabine 65 Sustained Release 65 Protease Inhibitor 65 Placebo Controlled Study 65 Nucleoside 65 Clinical Efficacy 65 ritonavir boosted 64 Dose Escalation Study 64 Preclinical Data 64 fosbretabulin 64 Pegylated 64 Immunomodulatory 64 Solid Tumors 64 Chronic Hepatitis C 64 Clinical Outcome 64 Receptor Antagonists 64 Oligonucleotides 64 Pharmacological 64 Cannabinoid 64 Presents Preclinical Data 64 Cyclophosphamide 64 Randomized Double blind 64 Novel Oral 64 Bioavailability 64 Hemodialysis Patients 64 PEG IFN 64 Peginterferon Alfa 2a 64 5 Fluorouracil 63 Single Dose 63 Antiangiogenic 63 Attenuates 63 Dendritic Cells 63 Clinical Trial Results 63 Relapsing Multiple Sclerosis 63 Previously Treated 63 Peginterferon 63 Potent Inhibitor 63 Investigational Compound 63 Liposomal 63 Pharmacokinetic PK 63 Drug Candidate 63 Pharmacodynamic 63 Phase 2b Clinical Trial 63 Randomized Double Blind 63 Fondaparinux 63 Estrogen Receptor 63 Potent Antiviral Activity 63 Chemotherapeutic Agents 63 Demonstrated Significant 63 Meta Analysis 63 Low Dose 63 Drug Metabolism 63 Novel Inhibitor 63 Cytotoxic 63 Pegylated Liposomal Doxorubicin 62 Antigen Specific 62 Phase 2b Study 62 Phase IIb Clinical Trial 62 Dose Escalation 62 Abstract Number 62 II Clinical Trial 62 Patients Treated With 62 amprenavir 62 Monotherapy 62 Mouse Model 62 Plus Ribavirin 62 alpha 2a 62 Antiviral Therapy 62 Novel Therapeutic 62 Skeletal Muscle 62 Patients Treated 62 Receptor Agonist 62 Pramlintide 62 Pooled Analysis 62 dexamethasone Decadron 62 Tyrosine Kinase Inhibitor 62 Hormone Refractory Prostate Cancer 62 JAK Inhibitor 62 vitro cytotoxicity 62 Inhibits 62 Immune Responses 62 Glatiramer Acetate 62 Present Preclinical Data 62 Abstract # 62 Inhalation Solution 62 plasma pharmacokinetics 62 Presents Positive 62 Progenitor Cells 62 Tiotropium 62 Poster Presentation 62 Unfractionated Heparin 62 Receptor Antagonist 62 Kinase Inhibitors 62 J Clin 62 HDAC Inhibitor 62 Pulmonary Arterial Hypertension 61 Investigational Drug 61 Reductase 61 Enoxaparin 61 Vitro Activity 61 Meets Primary Endpoint 61 Adefovir 61 Celecoxib 61 Dexamethasone 61 Bosutinib 61 liposome injection 61 Antitumor 61 Intracellular 61 Ranolazine 61 Cytotoxicity 61 Melphalan 61 Antipsychotic 61 Modulates 61 Hypercholesterolemia 61 humanized anti 61 Bivalirudin 61 Mg Uk 61 Decitabine 61 Interferon Beta 61 Darbepoetin Alfa 61 Acute Ischemic Stroke 61 Late Breaker 61 Cytochrome P# 61 Phase 2a Clinical Trial 61 Neuroprotection 61 Preclinical Study 61 Patients Receiving 61 pharmacokinetics 61 Oral Insulin 61 Treating Chronic 61 Ziprasidone 61 Extended Release 61 Adjunctive Therapy 61 Pioglitazone 61 Beneficial Effects 61 Arch Neurol 61 Phase III Clinical Trial 61 Intranasal 61 SABCS 61 Renal Cell Carcinoma 61 Sapacitabine 61 Prospective Randomized Trial 61 Kidney Function 61 Newly Diagnosed Multiple Myeloma 61 Benign Prostatic Hyperplasia 61 Phase 2a Trial 61 Protease Inhibitors 61 PEGylated Fab fragment 61 Anthracycline 61 Azacitidine 61 coadministration 61 Replacement Therapy 61 Polymerase Inhibitor 61 TO AVOID PREGNANCY WHILE 61 Epoetin Alfa 61 Combination Therapy 61 Conjugated 60 Phase IIb Trial 60 Tigecycline 60 inhibitor RG# 60 Hepatitis C Genotype 60 Phospholipase A2 60 Demonstrates Efficacy 60 Receives Orphan Drug Designation 60 Phosphorylation 60 Oritavancin 60 Tumor Response 60 Insulin Resistance 60 Pegylated Interferon 60 Randomized Phase 60 Phase 2b Trial 60 Tolerability Study 60 octreotide acetate 60 pharmacodynamic parameters 60 Lubiprostone 60 Anti Inflammatory 60 Estradiol 60 Smooth Muscle 60 Hepatocellular Carcinoma 60 Hsp# Inhibitor 60 Pivotal Phase III 60 Partial Onset Seizures 60 Phase IIa Clinical Trial 60 Gemcitabine 60 #:#-# [031] 60 oral prodrug 60 Pharmacologic 60 Anticancer Activity 60 Fulvestrant 60 HMG CoA reductase inhibitors 60 Radiofrequency Ablation 60 Inflammatory Arthritis 60 Systematic Review 60 2 methoxyestradiol 60 Complicated Skin 60 Humanized Anti 60 Therapeutic Efficacy 60 Anticancer Drug 60 IND Application 60 Statistically Significant 60 Hypertensive Patients 60 Drug Interactions 60 Clinical Trial Evaluating 60 Tumor Progression 60 Mimetics 60 Metabolic Efficiency 60 Preclinical Studies 60 Mycophenolate Mofetil 60 Refractory Hodgkin Lymphoma 60 guanfacine extended release 60 Bosentan 60 Bioequivalence 60 Completes Patient Enrollment 60 #:#-# [023] 60 Peginterferon Alfa 2b 60 Survival Benefit 60 zonisamide SR 60 biodistribution 60 Darunavir 60 Autologous Stem Cell Transplantation 60 Insulin Glargine 60 Clopidogrel 60 Blinatumomab 60 Phase III Trial 60 Myeloid 60 Excretion 60 SCH # 60 Metastatic Melanoma 60 Oxidative Stress 60 Adalimumab 60 Atypical Antipsychotic 59 Secondary Hyperparathyroidism 59 Transdermal Delivery 59 Dasatinib 59 nucleoside analog 59 Retinoic Acid 59 Postmenopausal Women 59 Elderly Patients 59 Treated Patients 59 Fixed Dose 59 Cardiotoxicity 59 Signaling Pathway 59 Randomised 59 Randomized Phase II 59 Statin Therapy 59 Oral Formulation 59 Initiate Phase 59 Transcriptional 59 Inflammatory Diseases 59 Exacerbation 59 Vidaza azacitidine 59 administered subcutaneously 59 Oral Presentation 59 Corticosteroid 59 Antiplatelet 59 atazanavir sulfate 59 pharmacokinetics PK 59 piroxicam 59 Fluticasone 59 Shows Efficacy 59 Dehydrogenase 59 Metastatic Prostate Cancer 59 unfractionated heparin UFH 59 Aflibercept 59 Hematological 59 Sulfonylurea 59 Adenosine 59 Hematologic 59 viral kinetics 59 Ropinirole 59 prucalopride 59 Interferon alfa 59 PEGylated anti 59 Safinamide 59 Biological Effects 59 Inhaled Liposomal Ciprofloxacin 59 TNF Tumor Necrosis Factor 59 Allogeneic 59 Metastatic Renal Cell Carcinoma 59 FASEB J. 59 Clinical Evaluation 59 systemically administered 59 Non Responders 59 Interferon Alfa 59 Pathogenesis 59 Novel Mechanism 59 dopamine D2 59 J Am Coll 59 alfa 2b 59 Analgesic 59 Nebulized 59 Subcutaneous 59 selective antagonist 59 Infected Patients 59 PEGylated interferon beta 1a 59 Randomized Clinical Trial 59 Endothelial 59 Int J 59 Omacetaxine 59 preclinical efficacy 59 fluticasone furoate 59 Signal Transduction 59 Versus Placebo 59 Potency 59 Efficacious 59 ROZEREM TM 59 Is Well Tolerated 59 Medoxomil 59 Tanespimycin 59 Kahalalide F 59 uricase 59 Randomized Study 59 Pediatric Patients 59 Induces 59 Lenalidomide 59 Molecular Basis 59 PRTX 59 Pafuramidine 59 Phase Ib Clinical Trial 59 Itraconazole 59 Metabolites 59 Trial Evaluating 59 Neoadjuvant 59 Aliskiren 59 Aclidinium 59 Free Full Text 59 Relapsed Refractory 59 Calcitonin 59 Crit Rev 59 Ribavirin 59 Toxicities 59 Mutagenesis 59 Initiates Phase 59 Targeted Therapy 59 Vildagliptin 59 Hepatic Encephalopathy 59 highly selective inhibitor 59 Castration Resistant Prostate Cancer 59 Prophylactic Treatment 58 Anti TNF 58 Abciximab 58 Therapeutic Potential 58 Intravesical 58 Chimeric 58 Initiates Clinical Trial 58 Sustained Efficacy 58 J Clin Oncol 58 alfa 2a 58 HCV SPRINT 58 Pivotal Phase 58 mecamylamine 58 Placebo Controlled 58 Lamotrigine 58 Teriflunomide 58 Trodusquemine 58 Antihypertensive 58 Pemetrexed 58 Nephrol 58 Posaconazole 58 HCV Genotype 58 Capsules CII 58 Lanthanum Carbonate 58 pharmacokinetic interactions 58 Danazol 58 Glucocorticoid 58 Tipranavir 58 direct thrombin inhibitors 58 Lacosamide 58 μg kg 58 Lp PLA 2 58 Protein Expression 58 polymerase inhibitor 58 MDS MPD 58 Randomized Controlled Trial 58 Inhalation Powder 58 histone deacetylase inhibitor 58 von Willebrand Factor 58 Investigational Agent 58 Diabetic Neuropathy 58 Cancer Res 58 Demonstrates Positive 58 Carfilzomib 58 Extracellular Matrix 58 icatibant 58 sorafenib Nexavar 58 Blind Placebo Controlled Trial 58 Romidepsin 58 Denufosol 58 Coadministration 58 Inhaled Corticosteroids 58 Submits NDA 58 pharmacodynamic PD 58 liposomal formulation 58 Luteinizing Hormone Releasing Hormone 58 Superoxide 58 A2A receptor 58 entitled Synergistic 58 Pharmacology 58 Telbivudine 58 posaconazole 58 pharmacokinetic parameters 58 Prospective Randomized 58 Sirolimus Eluting Stent 58 Multicenter Study 58 Natalizumab 58 Voreloxin 58 glatiramer acetate 58 Bone Metastases 58 intravenously administered 58 HCV Protease Inhibitor 58 pomalidomide 58 #mg BID [003] 58 Treatment Naive 58 Myelodysplastic Syndromes 58 Traficet EN 58 Hepatotoxicity 58 TNFalpha 58 Hematological Malignancies 58 nicardipine 58 Molecular Mechanism 58 Panzem R 58 Effectively Treats 58 Hematological Cancers 58 abacavir Ziagen 58 candesartan cilexetil 58 Nilotinib 58 Budesonide 58 Randomized Comparison 58 decitabine 58 Metabolic Disease 58 Endovascular Treatment 58 Tumor Biology 58 pharmacokinetic 58 efavirenz EFV 58 teriflunomide 58 Stent Restenosis 58 Venous Thromboembolism 58 rHuPH# 58 peripherally acting 58 lanreotide 58 Osteoporosis Treatment 58 Adenoma Prevention 58 Relapsed 58 prostanoid 58 PRN FDA Approves 58 R Saizen R 58 Curr Opin 58 medroxyprogesterone acetate 58 pharmacodynamic 58 mapatumumab 58 colesevelam 58 lanthanum carbonate 58 Clinical Study 58 AAG geldanamycin analog 58 dose proportionality 58 reuptake inhibitor 58 Cardiovascular Events 58 aspartate aminotransferase 58 Nuclear Receptors 58 Dosage Form 58 Patency 58 Genotypes 58 Sym# 58 Tesamorelin 58 #:#-# [029] 58 Methylprednisolone 58 Initiate Clinical Trial 58 abstr 58 Postmenopausal Osteoporosis 58 rabeprazole 58 AZILECT R 58 zoledronate 58 Severe Sepsis 58 Renal Function 58 pharmacokinetic PK 58 NDA Submission 58 Poster Session 58 Natural S equol 57 Abstract Free Full Text 57 BAL# [002] 57 peginterferon alpha 2a 57 Transdermal Patch 57 Amino Acid 57 Chronic Hepatitis B 57 Improves Outcomes 57 CrossRef Medline 57 Novel Treatments 57 Completes Enrollment 57 TRANSFORMS 57 J Am Soc 57 Cardiac Function 57 Incretin 57 First Patient Dosed 57 Myelodysplastic Syndrome MDS 57 Treatment Naive HIV 57 Infliximab 57 Significant Efficacy 57 Androxal TM 57 topically administered 57 Endothelial Cells 57 Prostatic 57 CDK inhibitor 57 Multiple Ascending Dose 57 Venlafaxine 57 Postmarketing 57 REP# 57 Fracture Risk 57 EMBO J. 57 Teriparatide 57 selective modulator 57 ribavirin USP 57 Proteasome 57 Releasing Factor 57 Cell Adhesion 57 Kidney Transplant Recipients 57 serotonin norepinephrine reuptake inhibitor 57 Perifosine 57 abacavir lamivudine 57 active metabolite 57 Paediatr 57 fluvastatin 57 Am J Clin 57 Patients Suffering 57 Sipuleucel T 57 CYP3A 57 Cilostazol 57 Study Showed 57 Cardiovascular Outcomes 57 Disease Progression 57 Cyclosporine 57 q#h 57 sulodexide 57 Preclinical Models 57 Polymorphism 57 colesevelam HCl 57 PK PD 57 Bevacizumab 57 Tocilizumab 57 Pharmacokinetic Pharmacodynamic 57 cholestyramine 57 Intracranial Aneurysms 57 Toremifene 57 J Nutr 57 EXPAREL ™ 57 PEGASYS ® 57 ISTODAX ® 57 Adjuvant Therapy 57 Successfully Completes Phase 57 Telithromycin 57 dual endothelin receptor antagonist 57 J Clin Endocrinol Metab 57 Hydrochloride 57 Xeloda ® 57 Inhaled 57 #-# Full Text 57 PKC# 57 Controlled Release 57 Nat Clin Pract 57 Blood Pressure Lowering 57 Interferon Gamma 57 Interferon alpha 57 Diabetic Nephropathy 57 huN# DM1 57 demonstrated antitumor activity 57 calcitonin 57 cytochrome P# #A# 57 Dose Ranging Study 57 alkylating agent 57 Chronic Renal Failure 57 cyanocobalamin 57 busulfan 57 Subgroup Analysis 57 sitaxsentan 57 Randomized Controlled 57 Toxicol 57 Universal Flu Vaccine 57 #:#-# [037] 57 Contrast Agents 57 VAPRISOL 57 PXD# 57 Pivotal Study 57 Tumor Angiogenesis 57 Eszopiclone 57 Interferon beta 1a 57 INCB# [003] 57 Immunotherapeutic 57 REYATAZ R 57 Unresectable 57 Demonstrates Sustained 57 interferon alfa 2b 57 Tolvaptan 57 J Am Acad 57 Valortim R 57 doxorubicin cyclophosphamide 57 #:#-# [022] 57 Fludarabine 57 orally bioavailable 57 Oncologic 57 DOXIL 57 Valsartan 57 danazol 57 Aortic Stenosis 57 Antisense Oligonucleotides 57 #:#-# [035] 57 Investigational Treatment 57 Omacetaxine mepesuccinate 57 Inactivation 57 Prophylaxis 57 azacytidine 57 APTIVUS 57 orally dosed 57 Ezetimibe 57 Phase III Clinical Trials 57 Heart Failure Patients 57 Inflammatory Pain 57 ISTODAX 57 VP# [004] 57 mg kg BID 57 fosamprenavir 57 Pharmacoepidemiology 57 ara C 57 #:#-# [028] 57 Schizophrenia Treatment 57 Demonstrates Statistically Significant 57 EZN 57 HCV protease 57 ug kg 57 Diabetic Patients 57 alfuzosin 57 Neurol 57 selective inhibition 57 Ambrisentan 57 Adjunctive 57 Dapagliflozin 57 Percutaneous Tibial Nerve Stimulation 57 Induction Therapy 57 xenograft models 57 H2 antagonists 57 interferon IFN 57 Disease Severity 57 Novel Compound 57 Fluorouracil 57 Motility 57 Etoposide 57 depsipeptide 57 Adjuvant Treatment 57 Overactive Bladder 57 Demonstrates Significant 57 intravesical 57 elastase 57 moderate hepatic impairment 57 #:#-# [020] 57 ACE Inhibitors 57 Preclinical 57 Advanced Pancreatic Cancer 57 Immunogenic 57 Demonstrates Potential 57 Induction Chemotherapy 57 ziprasidone 57 LEP ETU 57 Degarelix 57 Retrovirus 57 Neuroprotective Effects 57 Poster Discussion 57 Immunosuppression 57 Anti Infective 57 Studien 57 Menstrual Pain 57 subcutaneously administered 57 intranasal formulation 57 beta2 agonist 57 Appears Safe 57 Cytarabine 57 Tablet Formulation 57 Preclinical Development 57 #:#-# [006] 57 tartrate 57 fluorouracil leucovorin 56 histone deacetylase HDAC inhibitor 56 novel histone deacetylase 56 vidofludimus 56 Cellular Immunotherapy 56 Systemic Sclerosis 56 Bare Metal Stents 56 Relapsed Refractory Multiple Myeloma 56 PRT# 56 azacitidine 56 vinca alkaloid 56 calcipotriene 56 Microplasmin 56 Treatment Resistant 56 Advanced Prostate Cancer 56 platelet inhibitor 56 FOLOTYN ® 56 Intravitreal 56 Thrombotic 56 myelodysplastic myeloproliferative diseases 56 Breast Cancer Metastasis 56 Anti VEGF 56 Dosing Regimen 56 Sitagliptin 56 Triapine R 56 KRN# 56 CCX# B 56 Aripiprazole 56 Bicalutamide 56 5 HT1A receptor 56 Eculizumab 56 Disease Modifying 56 mGluR5 NAM 56 Fibrinogen 56 epoetin alpha 56 Raltegravir 56 Epithelial 56 Tumor Cell 56 Adjuvant Chemotherapy 56 Neurogenesis 56 adrenomedullin 56 analgesic efficacy 56 Deforolimus 56 albiglutide 56 Phase 2a Study 56 Isavuconazole 56 Elvitegravir 56 Bare Metal Stent 56 Mol Cell 56 Suicidality 56 antiplatelet agent 56 pralatrexate injection folate analogue 56 Treatment Naive Patients 56 Therapeutic Targets 56 Pharmacokinetic Profile 56 antineoplastic 56 KSP inhibitor 56 Knee Osteoarthritis 56 Patients Undergoing 56 Non Inferiority 56 aripiprazole Abilify 56 Randomized Evaluation 56 Brain Metastases 56 Left Ventricular Dysfunction 56 intravenous dosing 56 Dry Powder Inhalers 56 Immunologic 56 Improves Survival 56 Monoclonal Antibodies 56 Advanced Melanoma 56 docetaxel Taxotere ® 56 Carcinogenesis 56 Clostridium difficile Infection 56 Inflammatory Disease 56 selective agonist 56 cynomolgus monkeys 56 Methylnaltrexone 56 Improve Survival 56 Significantly Improves 56 inhibitory effects 56 GMX# 56 Zoledronic Acid 56 Trastuzumab 56 NMDA antagonists 56 serum leptin 56 oral rivaroxaban 56 hydroxocobalamin 56 tocilizumab 56 Genetic Variation 56 piperacillin tazobactam 56 pyrazinamide 56 Rheumatoid Arthritis Patients 56 Intramuscular 56 dose escalation clinical 56 effector function 56 Naive Patients 56 sunitinib Sutent ® 56 Androgen 56 Suppl 56 Liver Injury 56 Suppl. 56 dopamine reuptake 56 Mechanistic 56 davunetide intranasal AL 56 ascending doses 56 Osteoarthritis Pain 56 Seliciclib 56 HGS ETR2 56 NOXAFIL Oral Suspension 56 Combination Treatment 56 Gastric Cancer 56 pharmacokinetic PK study 56 ACTOS ® 56 Efficacy Results 56 Tumor Growth 56 Cinacalcet 56 suppl #S 56 EGFR HER2 56 Radiation Induced 56 Randomized Controlled Trials 56 idarubicin 56 Postprandial 56 Immune Globulin 56 Protein Kinase 56 MGd 56 Vivo Efficacy 56 Irinotecan 56 8mg/kg 56 RE LY trial 56 Urol 56 Desvenlafaxine Succinate 56 amifostine 56 Linagliptin 56 #:#-# [025] 56 Osteopontin 56 antidiabetic 56 monoamine oxidase inhibitors 56 ORENCIA ® 56 Oxidative 56 5 HT2A 56 REG2 56 Molecular Weight Heparin 56 Ophthalmol 56 Belerofon 56 nab paclitaxel 56 intramuscularly 56 racemic 56 Rotavirus Vaccine 56 Stent Implantation 56 Fast Skeletal Troponin 56 #S #S [003] 56 pharmacodynamics 56 bosentan 56 Doxepin 56 vapreotide acetate 56 Orthop Surg 56 Improved Survival 56 Anti CD# Antibody 56 muscarinic 56 nelfinavir 56 milatuzumab 56 anti CD3 56 Initiated Phase 56 Biomolecules 56 oral renin inhibitor 56 Cmax 56 Viral Suppression 56 J Pediatr 56 paricalcitol 56 Metastatic Colorectal Cancer 56 CA4P 56 #mg/#mg 56 Multicenter Randomized 56 extracellular signal 56 Respiratory Virus 56 EURIDIS 56 Pathophysiology 56 Valopicitabine NM# 56 Osteoporosis Drug 56 Mammalian Cells 56 Relapsing Remitting Multiple Sclerosis 56 FEMALES SHOULD BE ADVISED 56 Oral Mucositis 56 Hematologic Malignancies 56 Platelet Inhibition 56 desvenlafaxine succinate 56 tolerability profiles 56 Anticoagulant 56 Topical Gel 56 dose dependently 56 Eluting Stent 56 pathophysiological effects 56 Previously Untreated 56 Cethromycin 56 receptor monoclonal antibody 56 Gynecol Oncol 56 Localized Prostate Cancer 56 Darinaparsin 56 J Allergy Clin 56 itraconazole 56 AACR NCI EORTC 56 Genome Res 56 hematological parameters 56 Multicenter Phase 56 ALB # 56 Abstract Full Text 56 BARACLUDE ® 56 Demonstrate Significant 56 Uric Acid 56 Oral Session 55 Epratuzumab 55 Doxil ® 55 Phase III Trials 55 Protein Synthesis 55 Glucose Metabolism 55 mg TID 55 IFN α 55 cinacalcet 55 platelet inhibition 55 Preclinical studies suggest 55 prostaglandin E 55 anti leukemic 55 Blood Flow 55 estramustine 55 Bezielle 55 postmenopausal osteoporotic women 55 Prognostic Significance 55 Carbamazepine 55 lexidronam injection 55 antifibrotic 55 TRO# 55 ceftazidime 55 Akt activation 55 nitazoxanide 55 QD dosing 55 5 HT6 receptor 55 J Child Adolesc 55 subcutaneous SC 55 daunorubicin 55 Shows Statistically Significant 55 #mg #mg #mg [003] 55 microsomal 55 Proton Pump Inhibitors 55 LY# [003] 55 Aldosterone 55 erlotinib Tarceva ® 55 Moxifloxacin 55 J Natl Cancer Inst 55 LB# [003] 55 Bioorganic 55 TNF Alpha 55 Recombinant Protein 55 Menopausal Symptoms 55 dopamine partial agonist 55 immunomodulatory effects 55 malate 55 Antisense Drug 55 Drug Eluting 55 ZOLINZA 55 microglial activation 55 Paclitaxel Eluting 55 Preclinical Efficacy 55 Eur J 55 INSPIRE Trial Phase III 55 LT NS# 55 PI3K inhibitor 55 Rivaroxaban 55 delafloxacin 55 receptor antagonists 55 Somatostatin 55 pioglitazone HCl 55 Fenofibrate 55 CLORETAZINE TM VNP#M 55 melphalan prednisone 55 Myocardial Perfusion Imaging 55 Interferon beta 1b 55 primary hypercholesterolemia 55 dosage regimens 55 Olanzapine 55 Data Suggest 55 Chronic Heart Failure 55 RezularTM 55 cobalamin 55 Cell Proliferation 55 LEXIVA 55 Clinical Trial Data 55 Enzastaurin 55 murine 55 Nonclinical 55 Squalamine